XNOM message board

Guest

Here on this message board we are inviting all readers to discuss Xenomics, Inc. You may anonymously post comments with any information that they have about Xenomics, Inc.

Research Report

Hotstocked.com has a complete research report available for XNOM stock. Download XNOM report.

Research Report

Get the full report for FREE

Date:	Aug 13, 2009
Price:	Free
Pages:	5
Document Type:	Adobe Acrobat Reader
	Download XNOM report

Example preview:

Hotstocked · Guest

This message board is to discuss Xenomics, Inc stock. Post your opinion here.

Samuil Umansky M.d. · Guest

You can ask Google to remove this page http://www.google.com/support/websearch/ bin/answer.py?answer=92865

Guest

Doesn't the news show that there is future for Xenomics?

Xenomics Transrenal Technology Shows Significant Promise in Molecular Diagnostic Applications

Xenomics, Inc. (XNOM.PK), a developer of non-invasive next-generation molecular diagnostics, announced new data from a collaborative project with Dr. Warsof of Eastern Virginia Medical School, published on January 30th in the early online edition of the Clinical Chemistry. The data obtained in this new clinical study on detection of fetal gender by analysis of Transrenal DNA (Tr-DNA) isolated from maternal urine demonstrate 95.1% specificity in 173 pregnant women. Within a limited subset of urine samples, those collected in the first trimester, the test was 100% sensitive and 100% specific. These results were obtained when new proprietary methods of Tr-DNA isolation and analysis were applied for prenatal testing. Xenomics is currently developing its proprietary Tr-DNA/RNA technology for use in other tests, including early tumor detection and monitoring, diagnosis of infectious diseases, transplantation monitoring and other conditions.

The study, entitled “Optimization of Transrenal DNA Analysis: Detection of Fetal DNA in Maternal Urine” by Shekhtman et al., is available online in this week’s Early Edition of Clinical Chemistry at http://www.clinchem.org/

“Tr-DNA represents relatively short (50-200 bp) DNA fragments from cells throughout the body,” explained Dr. Samuil Umansky, Chief Scientific Officer and co-founder of Xenomics. “Thus, in order to effectively detect different biomarkers in urinary DNA we have developed a new method for isolation of such small molecules of cell-free DNA from urine and other bodily fluids. Several new approaches were used for detection of “ultrashort” (25-40 bp) DNA sequences by conventional and real time PCR. Taken together these two methods dramatically increased sensitivity of our Tr-DNA technology for prenatal and other applications.”

Dr. Warsof added, “This work demonstrates that fragments of fetal DNA can pass through the maternal kidney and be detected by completely non-invasive means, not even a blood draw. We can determine fetal gender earlier than ultrasound, and the implications may extend to prenatal diagnostics.”

As previously announced, Xenomics and Sequenom, Inc., a genetics and molecular diagnostics company (NASDAQ: SQNM), completed a licensing agreement that granted to Sequenom exclusive rights to Xenomics patents for the development of prenatal research and diagnostic products based on the Company’s proprietary Tr-DNA/RNA technology. The license does not cover the current Xenomics test for fetal gender determination reported in the article, which is based on detection of a Y chromosomal sequence.

About Xenomics

Xenomics is a molecular diagnostics company developing tests based on Transrenal nucleic acids (Tr-DNA and Tr-RNA including miRNA) and safe, simple urine collection techniques. The Company believes its proprietary technology has a broad range of detection / monitoring / screening applications, including prenatal conditions, infectious diseases, tissue transplantation, neurodegenerative disorders, various tumors, and can open significant new markets in the molecular diagnostics field. Currently, Xenomics is focusing on implementation of its urinary DNA-based test for high-risk Human Papilloma Virus (HPV) and development of other tests based on Tr-DNA and Tr-miRNA. Xenomics has a strong and broad IP portfolio of issued and pending patents covering different applications of the technology for molecular diagnostics.

Forward-Looking Statements

Statements about the Company's expectations, the significance of clinical study results, applications of its technology, markets, and other statements that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on management's current beliefs, assumptions, estimates and projections. Actual results may differ materially from those projected in the forward-looking statements for various reasons, including risks associated with product development, government regulation, market acceptance, dependence on key personnel, obtaining financing and other factors discussed in the Company's periodic reports filed with the Securities and Exchange Commission.

More information is available on the Company's website, www.xenomics.com.

Xenomics, Inc.
Dr. David Robbins, 908-489-9182
DRobbins@xenomics.com

I am starting to believe in this company! On the other hand, it's a pink sheet,a nd they can't be trusted. What is your opinion? Is this only the soap bubble which might shoot every min?